Nashville、TNにおける肺がんの臨床試験
Nashvilleとその周辺地域（約30マイル以内）の拠点で、肺がんに関する40件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
被験者募集中第1/2相
- Sarah Cannon Research Institute, Nashville
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
被験者募集中第2相
- SCRI Oncology Partners, Nashville
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
被験者募集中第1相
- SCRI Oncology Partners, Nashville
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
被験者募集中第3相
- SCRI Oncology Partners, Nashville
A Study of PHN-012 in Patients With Advanced Solid Tumors
被験者募集中第1相
- PHN-012-001 Site, Nashville
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
被験者募集中第3相
- SCRI Oncology Partners - Tennessee, Nashville
Phase 1 Study of PF-08046033 in Advanced Solid Tumors
被験者募集中第1相
- Sarah Cannon Research Institute- Pharmacy, Nashville
- SCRI Oncology Partners, Nashville
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
被験者募集中第3相
- Sarah Cannon Research Institute, Nashville
- United States Oncology Regulatory Affairs Corporate Office, Nashville
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
被験者募集中第3相
- SCRI Oncology Partners, Nashville
- Tennessee Oncology, PLLC-Elliston Place Plaza Medical Oncology &Hematology, Nashville
- Tennessee Oncology, PLLC - Saint Thomas West, Nashville
- 他3件
A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
被験者募集中第2相
- Sarah Cannon Research Institute, Nashville
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
被験者募集中第2相
- Research Site, Nashville
- Research Site, Nashville
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
被験者募集中第2/3相
- Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
被験者募集中第2/3相
- Tennessee Oncology, Nashville
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
被験者募集中第1/2相
- Sarah Cannon Research Institue, Nashville
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
被験者募集中第1/2相
- Tennessee Oncology, PLLC, Nashville
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
被験者募集中第1/2相
- Sarah Canon Research Institute (SCRI) Oncology Partners, Nashville
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
被験者募集中第1相
- Sarah Cannon Research Institute, Nashville
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
被験者募集中第1相
- Sarah Cannon Research Institute, Nashville
- SCRI Oncology Partners, Nashville
- Vanderbilt-Ingram Cancer Center, Nashville
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
被験者募集中第3相
- Tennessee Oncology, Nashville
- USO - US Oncology Research Network, Nashville
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
被験者募集中第1相
- SCRI Oncology Partners, Nashville
Collecting and Analyzing Tissue Samples From Patients Undergoing Surgery for Non-Small Cell Lung Cancer
被験者募集中観察研究
- Vanderbilt-Ingram Cancer Center, Nashville
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
被験者募集中第1/2相
- Sarah Cannon Research Institute Oncology Partners (SCRI-Nashville), Nashville
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
被験者募集中第1相
- Xencor Investigative Site, Nashville
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
被験者募集中第1/2相
- Tennessee Oncology, Nashville
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
被験者募集中第1相
- Sarah Cannon, SCRI Oncology Partners, Nashville
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
被験者募集中第1/2相
- Vanderbilt University Medical Center, Nashville
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
被験者募集中第1相
- Research Site, Nashville
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
被験者募集中第1相
- Sarah Cannon Research Institute, Nashville
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
被験者募集中第1/2相
- Sarah Cannon Research Institute, Nashville
Molecular Predictors of Cancer in Patients at High Risk of Lung Cancer
被験者募集中観察研究
- Vanderbilt-Ingram Cancer Center, Nashville
- Veterans Affairs Medical Center - Nashville, Nashville
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
被験者募集中第1/2相
- SCRI Oncology Partners, Nashville
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
被験者募集中第1相
- SCRI Oncology Partners, Nashville
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
被験者募集中第1相
- Sarah Cannon Research Institute (SCRI) Oncology Partners, Nashville
- Vanderbilt University Medical Center, Nashville
EBUS-TBNA vs Transbronchial Mediastinal Cryobiopsy for Adequacy of Next Generation Sequencing
被験者募集中第4相
- Vanderbilt University/Ingram Cancer Center, Nashville
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
被験者募集中観察研究健康なボランティア歓迎
- Vanderbilt-Ingram Cancer Center, Nashville
A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors
被験者募集中第1相
- Sarah Cannon Research Institute (SCRI), Nashville
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
被験者募集中観察研究
- Massive Bio SYNERGY-AI site, Nashville
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
被験者募集中第1/2相
- Tennessee Oncology, Nashville
Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer
被験者募集中第1/2相
- Vanderbilt University/Ingram Cancer Center, Nashville
Phase I/II Trial in ES-SCLC to Enhance Response to Atezolizumab Plus Chemotherapy With Total Body Irradiation
被験者募集中第1/2相
- Vanderbilt University/Ingram Cancer Center, Nashville
他の都市における肺がんの試験
- Houston, TX78件の研究
- Boston, MA62件の研究
- New York City, NY60件の研究
- Los Angeles, CA45件の研究
- Arlington, VA41件の研究
- Washington, DC41件の研究
- Chicago, IL41件の研究
- Baltimore, MD40件の研究
- St. Louis, MO39件の研究
- Columbus, OH37件の研究
- Philadelphia, PA36件の研究
- Seattle, WA33件の研究
Nashvilleにおける他の研究
- 非小細胞肺癌97件の研究
- 乳がん81件の研究
- 転移性癌70件の研究
- 大腸癌69件の研究
- がん（全種類）65件の研究
- 卵巣がん49件の研究
- 前立腺がん43件の研究
- 頭頸部扁平上皮癌39件の研究
- 膵臓がん39件の研究
- 子宮内膜がん38件の研究
- 悪性黒色腫33件の研究
- 多発性骨髄腫32件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。